Literature DB >> 14980220

Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.

Bingzhen Lin1, Siva Kumar Kolluri, Feng Lin, Wen Liu, Young-Hoon Han, Xihua Cao, Marcia I Dawson, John C Reed, Xiao-kun Zhang.   

Abstract

The Bcl-2 family proteins are key regulators of apoptosis in human diseases and cancers. Though known to block apoptosis, Bcl-2 promotes cell death through an undefined mechanism. Here, we show that Bcl-2 interacts with orphan nuclear receptor Nur77 (also known as TR3), which is required for cancer cell apoptosis induced by many antineoplastic agents. The interaction is mediated by the N-terminal loop region of Bcl-2 and is required for Nur77 mitochondrial localization and apoptosis. Nur77 binding induces a Bcl-2 conformational change that exposes its BH3 domain, resulting in conversion of Bcl-2 from a protector to a killer. These findings establish the coupling of Nur77 nuclear receptor with the Bcl-2 apoptotic machinery and demonstrate that Bcl-2 can manifest opposing phenotypes, induced by interactions with proteins such as Nur77, suggesting novel strategies for regulating apoptosis in cancer and other diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980220     DOI: 10.1016/s0092-8674(04)00162-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  248 in total

1.  Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells.

Authors:  Xi Li; Syng-Ook Lee; Stephen Safe
Journal:  Biochem Pharmacol       Date:  2012-03-03       Impact factor: 5.858

2.  Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax.

Authors:  Zhi Zhang; Suzanne M Lapolla; Matthew G Annis; Mary Truscott; G Jane Roberts; Yiwei Miao; Yuanlong Shao; Chibing Tan; Jun Peng; Arthur E Johnson; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

Review 3.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

4.  Regulation of vascular smooth muscle cell proliferation by nuclear orphan receptor Nur77.

Authors:  Liyue Wang; Fan Gong; Xiaoyan Dong; Wei Zhou; Qiutang Zeng
Journal:  Mol Cell Biochem       Date:  2010-04-22       Impact factor: 3.396

Review 5.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

6.  Cell death in mammalian cell culture: molecular mechanisms and cell line engineering strategies.

Authors:  Britta Krampe; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2010-05-26       Impact factor: 2.058

7.  Regulation of proteolytic cleavage of retinoid X receptor-α by GSK-3β.

Authors:  Weiwei Gao; Jie Liu; Mengjie Hu; Mingfeng Huang; Sisi Cai; Zhiping Zeng; Bingzhen Lin; Xihua Cao; Jiebo Chen; Jin-zhang Zeng; Hu Zhou; Xiao-kun Zhang
Journal:  Carcinogenesis       Date:  2013-02-06       Impact factor: 4.944

8.  1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth.

Authors:  Teruo Inamoto; Sabitha Papineni; Sudhakar Chintharlapalli; Sung-Dae Cho; Stephen Safe; Ashish M Kamat
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.

Authors:  Kumaravel Mohankumar; Xi Li; Subhashree Sridharan; Keshav Karki; Stephen Safe
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

10.  Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers.

Authors:  Yi-Fang Han; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.